ORION PHARMA LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 62.8 BDT | -2.94% |
|
-4.41% | -21.11% |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 9,688 | 7,769 | 9,828 | 12,613 | 20,592 | 18,626 |
| Enterprise Value (EV) 1 | 16,967 | 16,385 | 22,475 | 28,989 | 39,038 | 40,327 |
| P/E ratio | 12.1 x | 8.8 x | 14.8 x | 13.4 x | 24.3 x | 29.1 x |
| Yield | 3.62% | 4.52% | 2.38% | 2.23% | 1.14% | 1.26% |
| Capitalization / Revenue | 0.93 x | 0.89 x | 1.29 x | 1.16 x | 2.13 x | 1.34 x |
| EV / Revenue | 1.63 x | 1.88 x | 2.94 x | 2.68 x | 4.04 x | 2.9 x |
| EV / EBITDA | 7.41 x | 6.81 x | 9.13 x | 11.5 x | 33.7 x | 25.3 x |
| EV / FCF | -19.7 x | -10.5 x | -5.26 x | -792 x | -28.7 x | -13.2 x |
| FCF Yield | -5.09% | -9.56% | -19% | -0.13% | -3.48% | -7.57% |
| Price to Book | 0.57 x | 0.44 x | 0.55 x | 0.68 x | 1.07 x | 0.89 x |
| Nbr of stocks (in thousands) | 234,000 | 234,000 | 234,000 | 234,000 | 234,000 | 234,000 |
| Reference price 2 | 41.40 | 33.20 | 42.00 | 53.90 | 88.00 | 79.60 |
| Announcement Date | 11/27/18 | 11/30/19 | 12/1/20 | 11/29/21 | 12/11/22 | 12/15/23 |
1BDT in Million2BDT
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 10,423 | 8,705 | 7,648 | 10,833 | 9,662 | 13,927 |
| EBITDA 1 | 2,291 | 2,407 | 2,461 | 2,529 | 1,160 | 1,597 |
| EBIT 1 | 1,517 | 1,585 | 1,552 | 1,538 | 686.8 | 1,016 |
| Operating Margin | 14.55% | 18.21% | 20.3% | 14.2% | 7.11% | 7.29% |
| Earnings before Tax (EBT) 1 | 960.8 | 1,037 | 802 | 1,193 | 1,063 | 841.3 |
| Net income 1 | 801.8 | 882.4 | 665.7 | 939.1 | 846.1 | 640.9 |
| Net margin | 7.69% | 10.14% | 8.7% | 8.67% | 8.76% | 4.6% |
| EPS 2 | 3.426 | 3.771 | 2.845 | 4.013 | 3.616 | 2.739 |
| Free Cash Flow 1 | -863 | -1,567 | -4,271 | -36.58 | -1,358 | -3,052 |
| FCF margin | -8.28% | -18% | -55.84% | -0.34% | -14.06% | -21.92% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | 1.500 | 1.500 | 1.000 | 1.200 | 1.000 | 1.000 |
| Announcement Date | 11/27/18 | 11/30/19 | 12/1/20 | 11/29/21 | 12/11/22 | 12/15/23 |
1BDT in Million2BDT
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 7,280 | 8,616 | 12,647 | 16,377 | 18,446 | 21,700 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.177 x | 3.579 x | 5.138 x | 6.476 x | 15.91 x | 13.59 x |
| Free Cash Flow 1 | -863 | -1,567 | -4,271 | -36.6 | -1,358 | -3,052 |
| ROE (net income / shareholders' equity) | 5.07% | 5.27% | 3.89% | 5.73% | 4.36% | 3.22% |
| ROA (Net income/ Total Assets) | 3.22% | 3.21% | 2.86% | 2.43% | 0.95% | 1.26% |
| Assets 1 | 24,896 | 27,477 | 23,274 | 38,662 | 89,137 | 51,006 |
| Book Value Per Share 2 | 72.90 | 75.20 | 76.80 | 79.80 | 82.50 | 89.00 |
| Cash Flow per Share 2 | 2.170 | 0.3900 | 4.420 | 1.770 | 0.4500 | 0.5600 |
| Capex 1 | 998 | 1,348 | 1,543 | 4,277 | 2,667 | 3,859 |
| Capex / Sales | 9.57% | 15.49% | 20.18% | 39.48% | 27.6% | 27.71% |
| Announcement Date | 11/27/18 | 11/30/19 | 12/1/20 | 11/29/21 | 12/11/22 | 12/15/23 |
1BDT in Million2BDT
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -21.11% | 134M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ORIONPHARM Stock
- Financials Orion Pharma Limited
